DMCA

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

Cached

Download Links

by Charles D. Blanke , George D. Demetri , Margaret Von Mehren , Michael C. Heinrich , Burton Eisenberg , Jonathan A. Fletcher , Christopher L. Corless , Christopher D. M. Fletcher , Peter J. Roberts , Daniela Heinz , Elisabeth Wehre , Zariana Nikolova , Heikki Joensuu
Citations:2 - 0 self